Dementia-related disorders: Mild cognitive impairment (MCI), Alzheimer'
Conditions
Interventions
PET scanning: Two of the following four synaptic radioligands are selected based on disease and ligand characteristics and administered to patient groups, healthy volunteers receive up to three ligand
Sponsors
National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient group Participants must have the capacity to provide informed consent and be able to read and understand the informed consent document. In cases where the patient lacks decision-making capacity, a legally authorized representative must be able to accompany them on the day of study participation at QST. Aged 18 years or older at the time of informed consent. Patients diagnosed with one of the following conditions: dementia-related disorders (mild cognitive impairment, Alzheimer's disease, frontotemporal lobar degeneration, chronic traumatic encephalopathy), movement disorders (dystonia, Parkinsonism, essential tremor), epilepsy, or psychiatric disorders (mood disorders, schizophrenia, obsessive-compulsive disorder, anxiety disorders). Diagnostic criteria for each condition are as follows: 1 MCI: Patients meeting the Petersen diagnostic criteria 2 AD: Patients meeting the NINCDS-ADRDA diagnostic criteria 3 Frontotemporal lobar degeneration 4 Chronic traumatic encephalopathy 5 Dystonia 6 Parkinsonism 7 Essential tremor 8 Epilepsy 9 Mood disorders 10 Schizophrenia 11 Obsessive-compulsive disorder 12 Anxiety disorders Healthy volunteer group Aged 18 years or older at the time of informed consent. Healthy individuals who have the capacity to provide informed consent and are able to read and understand the informed consent document.
Exclusion criteria
Exclusion criteria: Patient group 1. Individuals with organic brain disorders (e.g., disturbance of consciousness, head trauma requiring hospitalization, or evident cerebral infarction or hemorrhage) 2. Individuals with comorbid substance-related disorders (e.g., drug dependence) 3. Individuals with severe comorbid medical conditions, or those with a history of such conditions, who are judged by the investigator to be inappropriate for participation in this study 4. Individuals with severe claustrophobia 5. Individuals who are pregnant, possibly pregnant, or breastfeeding 6. Individuals judged by the investigator to be unsuitable as study participants for any other reason Healthy volunteer group 1. Individuals with organic brain disorders (e.g., disturbance of consciousness, head trauma requiring hospitalization, or evident cerebral infarction or hemorrhage) 2. Individuals with substance-related disorders (e.g., drug dependence) 3. Individuals with severe comorbid medical conditions, or those with a history of such conditions, who are judged by the investigator to be inappropriate for participation in this study 4. Individuals with pacemakers or metallic implants (e.g., intracranial clips, bolts) 5. Individuals with tattoos (including cosmetic tattoos or permanent makeup) 6. Individuals with severe claustrophobia 7. Individuals who are pregnant, possibly pregnant, or breastfeeding 8. Individuals judged by the investigator to be unsuitable as study participants for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution and density of synaptic function-related proteins (SV2A, mGlu2/3 receptors, mGlu5 receptor, and AMPA receptor) in healthy controls and patient groups, as quantified by binding indices derived from PET imaging (e.g., BP_ND, V_T, and SUVR). | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Longitudinal changes in the distribution and density of the aforementioned synaptic function-related proteins in healthy controls and patient groups (follow-up comparison). (2) Associations and correlations between PET quantitative indices and clinical symptom scores, MRI measures (gray matter volume, diffusion tensor indices, resting-state functional connectivity, etc.), and blood biomarkers. (3) Comparisons of synaptic function indices across disease groups. | — |
Countries
Japan
Contacts
Public ContactYasuharu Yamamoto
National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science Advanced Neuroimaging Center
Outcome results
None listed